total of 449 results from PubMed (130), Embase (190) , and Web of Science (129). There were 352 results after removal of duplicates. The search was supplemented by reviewing the reference lists of relevant publications. Studies were grouped according to screening approach or teleophthalmology strategies.
Results
After excluding studies examining frequency intervals, we identified 18 studies assessing cost-effectiveness of different screening approaches (eg, who performs screening, opportunistic vs systematic screening), different delivery modalities (eg, clinic camera, telemedicine), and factors that influence success ( Table 1) .
Systematically screening patients (through structured screening programs), at the population level is complex, but can outperform opportunistic screening, which usually covers a minority of patients with diabetes in developed countries (Table 1) . 13, 14 In contrast to clinical examination, telemedicine reduces the burden in the eye clinic and improves access in remote environments. Maberley et al 10 reported that over 10 years, 67 versus 56 sight years were saved with telemedicine ($3900 vs $9800 per sight year and $15 000 vs $37 000 per QALY) compared to no screening. Photographer medical qualifications influence the specificity but not sensitivity of DR detection. 15 The use of trained photographic graders in lieu of physicians, is especially valuable in low or middle income regions where the number of ophthalmologists per capita is often lower compared to developed countries. 13, 16 Cost-effective telemedicine programs have been reported in a variety of settings, including the United States, Canada, United Kingdom, India, and Norway (Table 1) . 10, [17] [18] [19] [20] [21] Telemedicine programs are more cost-effective in people who derive more benefit. For example, populations have more benefit when screened at a younger age, using insulin, higher HbA1c, faster HbA1c change rates, or with high transportation costs. 17, 18, 22, 23 In addition, population size and disease burden can determine the cost-effectiveness of a screening program such that screening a low number of individuals is not economically sound. 18, 20, 24 One common target is omission of pupillary mydriasis. This facilitates increased brevity of the screening encounter, comfort for the patient, and overall acceptance. Results from studies evaluating nonmydriatic approaches perform favorably and are cost-effective. 10, 13, 19, 21, 25, 26 Interestingly, the need to pay for care seems to affect usage. Results from a recent randomized trial, evaluating the inverse care law in a DR screening program, showed that paying for the screening (US$8) resulted in a lower uptake of screening than being provided with free screening (OR, 0.59). Paying also resulted in a lower detection rate of DR (OR, 0.73) after adjustment for potential confounding factors. Subjects with higher income or living in better housing were more likely to be screened but less likely to have DR detected, suggesting that those in greatest need might be less able to access care. 27 Free systematic DR screening can be a cost-effective option if the health care system is willing to invest US$16 000 per QALY gained. 28 The effectiveness of DR screening intervals has been examined in recent systematic reviews. 5, 6 Echouffo-Tcheugui et al concluded that in patients without DR, screening intervals could safely and effectively be extended to 2 years unless the individuals had poor glycemic control or uncontrolled hypertension. 5 A similar systematic review by Taylor-Phillips et al found similar results but arrived to a different conclusion, suggesting that current evidence does not support a shift to screening intervals beyond 1 year, given the lack of experimental research design and heterogeneity in definition of those at low risk. 6 Current recommendations by the American Diabetes Association suggest that if there is no evidence of DR for 1 or more evaluations, then screening every 2 years may be considered, however if DR is present subsequent examinations should be repeated annually or more frequently by an ophthalmologist or optometrist. 29 Advancements in technology could enable improved access to care, but data for recent telemedicine and newer technological approaches is yet limited. Alternative screening innovations such as optical coherence tomography, handheld fundoscopy, and other cell-phone-based techniques have been introduced. [30] [31] [32] [33] [34] [35] The ubiquity and relative low cost of smartphones with cameras makes for an attractive platform for both image acquisition, 21 interpretation, 33 and transmission. 30 Techniques using a handheld condensing lens paired with a smartphone camera can capture images at a relatively low cost. 31, 32, 35 Recently, Ryan et al reported a prospective comparative study of 3 modalities including: smartphone fundus photography, nonmydriatic fundus photography, and 7-field mydriatic fundus photography. The smartphone is able to detect DR and sight threatening disease, but at a lower sensitivity compared to nonmydriatic fundus photography. 36 The economic and clinical feasibility of newer technologies in teleophthalmology need to be further investigated.
Conclusions
Establishing mechanisms to reach populations with geographic and financial barriers to access is essential to prevent visual disability globally. Current screening strategies aimed at detection of DR have poor compliance. [37] [38] [39] Further compounding the challenge is that nearly 80% of all persons with diabetes live in LMICs.
Mydriatic 7-field photography or clinical fundus examination are considered to be the gold standard for DR screening. 15 Screening modalities can vary according to instrument used (eg, film, Polaroid, scanning laser or digital photography; slit lamp, direct and indirect ophthalmoscope), mydriatic status, number of photographic fields, and qualifications of the photographer and interpreter. The sensitivity of detecting DR depends on the training of individual. In general, ophthalmic personnel outperform nonophthalmic personnel at accuracy of screening for DR. 13 However, to improve access, teleophthalmology will likely be the cornerstone of most DR screening programs. This strategy has flaws. The need for photography depends on the equipment, which can be cost prohibitive for many systems. 14 Skill is required for image acquisition and interpretation, 18, 40 and action must then be taken to provide the definitive care when deemed necessary with appropriate referral to the ophthalmologist. Mobile programs help solve the geographic access problem, 41 but equipment cost remains prohibitive for routine providers and communities that are not supported by governments or foundations.
Recommendations
Cost-effective strategies and technology to provide wide coverage are necessary. This is particularly important for regions where the ratio of providers and distance to reach them is most prohibitive, and large gaps exist. To improve the status quo, several options can be considered: (1) economic viability may be improved by decreased screening frequency in low risk individuals; 5, 29, 42 (2) to improve geographic access, governments and health care payers may consider teleretinopathy screening programs; (3) modern nonmydriatic cameras should be considered when economically feasible; (4) to improve economic viability, more portable and less expensive equipment to detect diabetic retinopathy can be considered, recognizing the trade off in performance, 30, 32, 33, 35 and supporting the acceleration of this research may have important economic and social benefits.
The ideal screening technology must be portable, noninvasive, reliable, and easy to use by relatively unskilled persons. Testing must be deployed in areas with sufficient volume of patients that resources spent on travel cover the cost reduction in preventing blinding disease. 18, 20 The objective of screening programs is to identify individuals who will benefit from sight saving laser therapy. As such, the final obstacle to overcome for successful implementation of these screening programs is to partner with an ophthalmologist who can deliver timely laser treatment when indicated.
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